Literature DB >> 34923098

Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach.

Rohil Malpani1, Christopher W Petty1, Junlin Yang1, Neha Bhatt1, Tal Zeevi1, Vijay Chockalingam1, Rajiv Raju1, Alexandra Petukhova-Greenstein1, Jessica Gois Santana1, Todd R Schlachter1, David C Madoff1, Julius Chapiro2, James Duncan1, MingDe Lin3.   

Abstract

PURPOSE: To show that a deep learning (DL)-based, automated model for Lipiodol (Guerbet Pharmaceuticals, Paris, France) segmentation on cone-beam computed tomography (CT) after conventional transarterial chemoembolization performs closer to the "ground truth segmentation" than a conventional thresholding-based model.
MATERIALS AND METHODS: This post hoc analysis included 36 patients with a diagnosis of hepatocellular carcinoma or other solid liver tumors who underwent conventional transarterial chemoembolization with an intraprocedural cone-beam CT. Semiautomatic segmentation of Lipiodol was obtained. Subsequently, a convolutional U-net model was used to output a binary mask that predicted Lipiodol deposition. A threshold value of signal intensity on cone-beam CT was used to obtain a Lipiodol mask for comparison. The dice similarity coefficient (DSC), mean squared error (MSE), center of mass (CM), and fractional volume ratios for both masks were obtained by comparing them to the ground truth (radiologist-segmented Lipiodol deposits) to obtain accuracy metrics for the 2 masks. These results were used to compare the model versus the threshold technique.
RESULTS: For all metrics, the U-net outperformed the threshold technique: DSC (0.65 ± 0.17 vs 0.45 ± 0.22, P < .001) and MSE (125.53 ± 107.36 vs 185.98 ± 93.82, P = .005). The difference between the CM predicted and the actual CM was 15.31 mm ± 14.63 versus 31.34 mm ± 30.24 (P < .001), with lesser distance indicating higher accuracy. The fraction of volume present ([predicted Lipiodol volume]/[ground truth Lipiodol volume]) was 1.22 ± 0.84 versus 2.58 ± 3.52 (P = .048) for the current model's prediction and threshold technique, respectively.
CONCLUSIONS: This study showed that a DL framework could detect Lipiodol in cone-beam CT imaging and was capable of outperforming the conventionally used thresholding technique over several metrics. Further optimization will allow for more accurate, quantitative predictions of Lipiodol depositions intraprocedurally.
Copyright © 2021 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34923098      PMCID: PMC8972393          DOI: 10.1016/j.jvir.2021.12.017

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  29 in total

Review 1.  Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria.

Authors:  Ron C Gaba; Robert J Lewandowski; Ryan Hickey; Mark O Baerlocher; Emil I Cohen; Sean R Dariushnia; Bertrand Janne d'Othée; Siddharth A Padia; Riad Salem; David S Wang; Boris Nikolic; Daniel B Brown
Journal:  J Vasc Interv Radiol       Date:  2016-02-02       Impact factor: 3.464

2.  Cerebral CT perfusion using an interventional C-arm imaging system: cerebral blood flow measurements.

Authors:  A Ganguly; A Fieselmann; M Marks; J Rosenberg; J Boese; Y Deuerling-Zheng; M Straka; G Zaharchuk; R Bammer; R Fahrig
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-14       Impact factor: 3.825

Review 3.  CBCT-based bone quality assessment: are Hounsfield units applicable?

Authors:  R Pauwels; R Jacobs; S R Singer; M Mupparapu
Journal:  Dentomaxillofac Radiol       Date:  2015       Impact factor: 2.419

4.  Comparison of an adaptive local thresholding method on CBCT and µCT endodontic images.

Authors:  Jérôme Michetti; Adrian Basarab; Franck Diemer; Denis Kouame
Journal:  Phys Med Biol       Date:  2017-12-19       Impact factor: 3.609

5.  Accelerating the Translation of Artificial Intelligence From Ideas to Routine Clinical Workflow.

Authors:  MingDe Lin
Journal:  Acad Radiol       Date:  2020-01       Impact factor: 3.173

6.  Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?

Authors:  Romaric Loffroy; MingDe Lin; Gayane Yenokyan; Pramod P Rao; Nikhil Bhagat; Niels Noordhoek; Alessandro Radaelli; Järl Blijd; Eleni Liapi; Jean-François Geschwind
Journal:  Radiology       Date:  2012-11-09       Impact factor: 11.105

7.  C-Arm Conebeam CT Perfusion Imaging in the Angiographic Suite: A Comparison with Multidetector CT Perfusion Imaging.

Authors:  K Niu; P Yang; Y Wu; T Struffert; A Doerfler; S Schafer; K Royalty; C Strother; G-H Chen
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-18       Impact factor: 3.825

8.  Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT.

Authors:  Rongxin Chen; Jean-François Geschwind; Zhijun Wang; Vania Tacher; MingDe Lin
Journal:  J Vasc Interv Radiol       Date:  2013-10-01       Impact factor: 3.464

9.  A Novel CT to Cone-Beam CT Registration Method Enables Immediate Real-Time Intraprocedural Three-Dimensional Assessment of Ablative Treatments of Liver Malignancies.

Authors:  Marco Solbiati; Katia M Passera; S Nahum Goldberg; Alessandro Rotilio; Tiziana Ierace; Vittorio Pedicini; Dario Poretti; Luigi Solbiati
Journal:  Cardiovasc Intervent Radiol       Date:  2018-02-28       Impact factor: 2.740

10.  Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer.

Authors:  Milena A Miszczuk; Julius Chapiro; Jean-Francois H Geschwind; Vinayak Thakur; Nariman Nezami; Fabian Laage-Gaupp; Michal Kulon; Johanna M M van Breugel; Arash Fereydooni; MingDe Lin; Lynn Jeanette Savic; Bruno Tegel; Tamara Wahlin; Eliot Funai; Todd Schlachter
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.